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The evidence for switching dibenzazepines in people with epilepsy 
Abstract 
The dibenzazepines particularly carbamazepine are associated with known adverse effects (AEs) and 
drug to drug interactions. Eslicarbazepine acetate (ESL) is structurally distinct from other members 
of the dibenzazepine family and has the advantage of once daily dosing. Observational and trial data 
report successful switching from older dibenzazepines to ESL. The evidence base for   doing so is 
unclear and not standardised. This is a literature review following the PRISMA scoping guidelines 
identifying the evidence of switching dibenzazepines. Transition methods, ratios, tolerance to 
change, adverse effects and retention post change were evaluated. Study quality was assessed using 
the Oxford Centre for Evidence Based Medicine levels of evidence. Seven studies investigated the 
outcome of transition between carbamazepine and or oxcarbazepine to ESL, with specific data on 
the transition dose ratio and scheduling.  The available data suggest that the overnight transition 
between oxcarbazepine and ESL in a 1:1 ratio (most common) is generally well tolerated with high 
retention rates.  The transition showed improvement in adverse events associated with 
oxcarbazepine across a variety of domains. Almost 60% transitioned because of adverse events 
experienced no further symptoms at 12 months.  There is less data on the transition from 
carbamazepine to ESL.  The evidence available suggests an overnight transition in the ratio of 1:1.3-
1.5.  The retention rate following transition from carbamazepine to ESL was 69% (follow up of four 
months) with almost half of those transitioned   because of adverse events experiencing no further 






The tolerability of AED regimes is crucial to treatment adherence, as non-concordance is a major 
cause of break-through seizures for people on long-term AEDs.1 Now that there is significant ‘real 
world’ experience alongside trial data with a newer AED, eslicarbazepine acetate, we review the 
available efficacy and tolerability data, particularly in comparison with standard AEDs. 
Eslicarbazepine acetate 
Eslicarbazepine acetate (ESL) is licensed in the United States and Europe as an adjunctive treatment 
for focal-onset seizures with or without progression to bilateral tonic clonic seizures for people with 
epilepsy aged 6 years and older; it can also be used in monotherapy in adults. ESL is structurally 
distinct from other members of the dibenzazepine family (carbamazepine (CBZ) and oxcarbazepine 
(OXC)). There is evidence to suggest that ESL may be better tolerated and more efficacious than 
older dibenzazepines, and ESL may be an effective adjunct in individuals previously treated 
ineffectively with CBZ.2 The dibenzazepines are associated with known adverse effects (AEs) 
including dizziness, nausea, hyponatraemia, osteopenia, and skin reactions. CBZ specifically has 
major potential for significant drug to drug interactions. CBZ is commonly associated with increased 
serum lipid levels, and there is potential for severe rebound seizures with both CBZ and OXC when 
adherence is low.3,4 A key difference between ESL and CBZ is the pharmacokinetic profile and 
metabolism which conveys real clinical utility.  Eslicarbazepine acetate has high bioavailability 
reaching peak concentration within two to three hours, with a significantly longer half-life of 20-24 
hours (depending on population studied).  This allows for once daily dosing and may minimise the 
risk of adverse events associated with CBZ and OXC, reduce the risk of drug to drug interactions, and 
increase concordance.5 
Efficacy and Safety, and tolerability 
A pooled analysis from four phase-3 randomised, double blind, placebo-controlled trials (N=1703) 
demonstrates that ESL was associated with a significant reduction in standardised seizure frequency 
(P<0.0001) at doses of 800mg (33%) and 1200mg (38%) when compared to placebo (18%).  The 
responder rates (≥ 50% reduction in seizures over 4 weeks) were 34% (800mg) and 43% (1200mg) 
compared to 22% in the placebo group.6 A post-hoc pooled analysis of three randomised, placebo-
controlled trials in adults with treatment resistant focal onset seizures assessed the safety (N=1447) 
of adjunctive ESL.7 ESL was generally well tolerated and treatment-related adverse events were dose 
related (lower incidence for those initiated at 400mg). Those adverse events leading to 
discontinuation were 28 (6.6%) in the placebo arm versus 179 (17.5%) in the ESL group.  Adverse 
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events overall also appeared to be dose related (19/196 at 400mg, 104/410 at 1200mg).  The overall 
incidence of serious adverse events was less than 10%.  The most common events leading to 
discontinuation in the ESL group were dizziness, nausea, and vomiting.7 
Monotherapy 
In the monotherapy setting, two trials including a total of 332 patients from multiple centres have 
described the efficacy of ESL in patients who were switched from CBZ and/or other AEDs.8 Patients 
on average, achieved a reduction of seizure frequency (calculated per 28 days) of 43% with ESL 1600 
mg, and 36% with ESL 1200 mg.  The magnitude of reduction was less for patients who were taking 
CBZ at baseline (12% on ESL 1200mg and 28% on ESL 1600mg) than for those who were not (45% on 
ESL 1200mg and 50% on ESL 1600mg).8 
The largest cohort of patients from real-word experience was analysed in the Euro-ESLI study, which 
assessed the effectiveness, safety and tolerability of ESL when used in everyday clinical practice in 
Europe.9 Data were obtained retrospectively from a number of heterogeneous clinical studies and 
pooled for analysis.  Data from 2058 patients were included. A total of 2058 patients were assessed 
for safety and 1975 patients were assessed for effectiveness.  AEs were reported for 34.0% of 
patients and led to discontinuation in 13.6% of patients.  At 12 months the overall responder rate (≥ 
50% reduction in seizures) was 76% with a seizure freedom rate of 41%.  Of the 2058 patients 
included in the total analysis, 233 (11%) were transitioned from CBZ to ESL.  163 of the 233 patients 
(70%) were responders at 12 months and the seizure freedom rate was 31%. Among patients who 
transitioned from CBZ to ESL due to lack of efficacy, 11 patients out of 105 demonstrated unchanged 
or worsened seizure frequency at 12 months.9 
The safety profile has also been reported in a small real-world study, which analysed 108 patients in 
Spain.10 Among 108 patients, 52% switched from older dibenzazepines (either CBZ or OXC). 
Laboratory values concerning lipid metabolism profile, liver function tests (LFTs) and sodium was 
assessed before and after switching treatment. Patients switching from prior dibenzazepines 
showed significant reductions in mean low-density lipoproteins (LDL) and triglycerides (p<0.05). No 
differences were detected in other mean lab values, including sodium levels.10 The Euro-ESLI data 
have undergone several further subgroup analyses, including specific investigation into 
monotherapy.  The data are concordant with observational evidence such as the prospective 
multicentre study in 17 hospitals in Spain which demonstrated a responder rate of 83% (N=49) at 12 
months, and adverse event rate of 15% (N=18).11 
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It is clear that clinicians are switching from CBZ and OXC to ESL but best practice for how to make the 
change is unclear. We review the evidence base for switching, specifically considering the mode of 
switching between AEDs (slow transition or immediate), dose ratio, and the impact upon safety, 
tolerability, and efficacy.   
Methods 
Inclusion/Exclusion criteria 
The PRISMA scoping review guidelines were followed (supplementary information 1). This review 
included randomised controlled trials and uncontrolled prospective and retrospective cohort studies 
reporting outcomes from a ‘switch’ between CBZ and/or OXC and ESL, including information on how 
this transition was achieved. Studies were included if they reported: data observing dose titration 
method (ratio) of switching to ESL from CBZ and/or OXC and compared either efficacy and/or 
safety/tolerability before and after switching. Outcome measures included adverse events, retention 
rate, responder rate (≥ 50% reduction in seizures), change in seizure frequency, and quality of life 
according to validated general scales such as the 36-Item Short Form Health Survey (SF-36), EuroQol 
5-Dimensions (EQ-5D), or epilepsy-specific scales such as the Quality Of Life In Epilepsy-31 (QOLIE-
31). Exclusion criteria included; no data on transition between dibenzazepines’, and lack of 
meaningful comparable outcome data. 
Search strategy 
A search was conducted on Medline (1946 to July 31st 2019), Embase, PsychINFO, and the Cochrane 
Library of Systematic Reviews using search terms and subject headings: eslicarbazepine and 
carbamazepine or oxcarbazepine with no language or date restrictions (appendix 1).   We reviewed 
the reference lists of retrieved trials to check for additional reports of relevant studies and included 
grey literature. 
Data collection and Analyses 
We reviewed the outcome data from each study in detail with a view to pooling results to help 
consolidate the evidence available.  There is dichotomous data available regarding responder rates, 
retention rates, and there are similar validated tools used to measure adverse events and quality of 
life outcomes across investigations.  However, the heterogeneity of methodologies suggests that a 
descriptive review would be more appropriate.  The barriers to pooling data include significant 
differences in; inclusion and exclusion criteria, follow-up period, ratio of transition between 





We identified 841 records that fulfilled the search criteria. Animal studies (30) and duplicate studies 
(209) were removed leaving 602 records. These records were screened with 564 excluded based on 
title and abstract. Full text screening of the remaining 38 records led to 31 being excluded due to no 
data on transition ratio between dibenzazepines (11) review articles (5), ESL monotherapy (4), no 
ESL data (3), erratum responses (2), duplicate data (3), pharmacokinetic study (1), only data on 
children (1), only lipid data (1).  Seven studies were included within this review (Table 1). 
Table 1 [INSERT HERE] 
All seven studies include data on the ratio and schedule of transition between dibenzazepines. Data 
are included on a total of 203 individuals; however two of the studies were sub-group analyses of 
larger populations. Of the seven studies, five were prospective, observational, uncontrolled, single-
centre designs. A sub-group analysis from a larger retrospective, multicentre, uncontrolled 
observational investigation was also included.  Because of limited data we also included conference 
abstracts (2) that met the inclusion criteria.  All seven studies included some data on tolerability and 
adverse events.  Four of the seven investigations included some data on efficacy. Seven studies 
reported on transition from OXC to ESL and two studies reported on the transition from CBZ to ESL. 
Due to heterogeneity in study design and dose schedules it was not possible to pool outcome data. 
The results are therefore presented as a narrative review. 
 
Transition dose ratio between AEDs 
No data on comparisons between switching regimes or dose ratio were identified for transitions 
between OXC and ESL, or CBZ and ESL. 
OXC to ESL 
The most common transition from OXC to ESL was an overnight switch in a ratio of 1:1 (5 studies, 
N=145).  One prospective observational study (N=19) initially transitioned with an overnight switch 
ratio of 1:0.7 (OXC: ESL), and then increased ESL dose to a ratio of 1:1 after 3 days treatment.12 
Another prospective study included observed an overnight switch in a varying dose ratio between 
1:1.1 and 1:1.9 (OXC: ESL).13 
CBZ to ESL 
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The review identified less data on the ratio of switch between CBZ and ESL (2 studies, N=58).  A sub-
group analysis (N=13) of a prospective observational study transitioned overnight in a ratio of 1:1.3 
(CBZ: ESL).14 A retrospective, multicentre study sub-group analysis (N=45) observed an overnight 
transition in a ratio of 1:1.5 (CBZ: ESL).15 
Efficacy 
OXC to ESL 
Three studies reported on efficacy outcomes in 84 patients switching from OXC to ESL.  An open-
label prospective observational study in Spain included 12 individuals as part of a larger cohort of 61 
patients with treatment resistant epilepsy, on a variety of concomitant AEDs.  The transition from 
OXC to ESL was conducted overnight in a dose ratio of approximately 1:1 (for example those 
prescribed OXC at 400mg were switched directly to ESL 400mg).  Eleven of those included were 
followed up for at least 3 months (mean follow-up time 5.25 ± 2.3 months).  One individual achieved 
seizure freedom, an additional 4 (36%) achieved ≥ 50 per cent reduction in seizure frequency, one 
experienced no change, and one experienced an increase in seizure frequency.14 
A retrospective multicentre study (N=327) in Spain (ESLIBASE) investigating individuals with focal 
seizures across 12 hospital sites over a 2-year period included 48 individuals who switched from OXC 
to ESL.  The transition from OXC to ESL was conducted overnight in a dose ratio of 1:1.  Investigators 
observed a 12 month responder rate (≥ 50 per cent reduction in seizure frequency) of 46%, a seizure 
freedom rate of 31% (baseline before inclusion 16%), and epilepsy worsened in 17%.15 A single 
centre study in Finland (N=23) followed individuals transitioned from OXC to ESL overnight in a dose 
ratio of 1:1. No significant change in seizure frequency was observed over a 1 to 3 month follow-up 
period.16 
CBZ to ESL 
The two Spanish studies discussed above also investigated the efficacy of switching from CBZ to ESL 
in a total of 58 participants.  The larger retrospective investigation included 45 participants that 
transitioned from CBZ to ESL.  This switch was made overnight in a dose ratio of 1:1.5 (CBZ: ESL).  
Investigators observed a 12-month responder rate of 39%, seizure freedom in 11% (baseline 13%), 
and epilepsy worsened in 17%.15 
Thirteen people with treatment-resistant epilepsy were transitioned from CBZ to ESL in a post-
authorisation observational study.  The switch was made overnight in a dose ratio of 1:1.3 (CBZ: 
ESL).  However, only 8 individuals who switched were monitored for at least 3 months.  In these 
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cases one patient remained seizure free, one responded, three demonstrated no significant change, 
and a further three experienced an undefined increase in seizure frequency.14 
Adverse Events 
All seven studies involving a total of 203 participants included within this review included some 
outcome measure related to adverse events.  In the prospective observational study conducted in 
Spain four of the 12 patients who switched from OXC to ESL (1:1 dose ratio) experienced the same 
adverse event: drowsiness. Two individuals reported that adverse events associated with OXC 
(dizziness and drowsiness) improved on switching to ESL.  The retention rate for the OXC to ESL 
group was 100% (mean follow up time was approximately 5 months).  In the CBZ to ESL (1:1.5 dose 
ratio) group 8 out of 13 patients’ experienced adverse events (dizziness and nausea, 4; anxiety, 2; 
insomnia, 1; constipation, 1; pruritic rash, 1).  The retention rate (mean follow up approximately 4 
months) for the CBZ to ESL group was 69%.14 
In the ESLIBASE subgroup analysis 26 individuals were switched to ESL from OXC (1:1 dose ratio) 
because of side effects.  Of those switched, 15 out of 26 no longer had any adverse effects, while for 
11 out of 26 the adverse effect continued.  Seventeen individuals were switched from CBZ to ESL 
(1:1.5) because of side effects.  Following transition 8 out of 17 no longer experienced adverse 
effects, 9 (53%) continued to experience adverse events.15 
In a single centre prospective study in the inpatient setting, 23 patients were specifically identified 
for transition from OXC to ESL (1:1 dose ratio) because of adverse events related to OXC.  Those 
included were most commonly on two other AEDs.  The adverse events reported prior to the switch 
were most commonly fatigue (almost 50%), followed by vertigo and dizziness.  Following the switch 
to ESL, 15 out of 23 patients experienced a significant reduction in adverse events.  Following 
transition, almost all (93%) of the adverse events that presented in the morning resolved.  The 
incidence of adverse events associated with ESL declined during follow up (39% at 1 month, 13% at 3 
months).  There was a 100% retention rate during the 3-month follow-up period.16 
A small prospective observational study (N=19) has demonstrated that a switch to ESL (dose ratio 
1:0.7, increased to 1:1 after 3 days) in individuals with focal epilepsy on high dose OXC, does not 
affect serum sodium levels.12 An overnight switch from OXC to ESL (dose ratio 1:1) was examined 
prospectively over a 5 day period with standardised testing before and after transition (n=12).  No 
significant differences were identified on measures of adverse events, quality of life, or alertness.  
Serum sodium level decreased in 9 out of 12 participants but never to a clinically significant level.17 
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A small (N=10) prospective observational investigation examined the tolerability of overnight switch 
(dose ratio variable 1:1.1 –1.9) in adults with uncontrolled focal seizures.  The mean dose after 
switching was 800mg.  Investigators applied the Adverse Event Profile (AEP), a standardized test for 
alertness, and the Quality of Life in Epilepsy Inventory-10 (QOLIE-10).  At day-5 following the switch 
to ESL there was a significant reduction in AEP scores (P=0.005).  There were no statistically 
significant differences on the other outcome measures.13 A retrospective, single centre study (N=21) 
in patients with treatment resistant focal seizures (81% temporal lobe epilepsy) also used similar 
outcome measures.  An overnight switch was performed between OXC and ESL (dose ratio 1:1) with 
AEP score and QOLIE-10 scores taken before the switch and 5 days post transition.  There were 
statistically significant improvements in AEP score (p<0.001), QOLIE-10 (p=0.001), and alertness 
(p<0.05) in the short term, with no comment on clinical significance.  The AEP score improved for all 
patients after switch.  The QOLIE-10 scores remained the same or worsened for 4 out of 21 patients.  
The alertness score (reaction time) remained unchanged or worsened in 5 out of 21. There was no 




In contrast to CBZ and OXC it has been shown that Esli appears to lack any clinically meaningful 
interaction with other enzyme inducing AEDs.5 This is of real clinical benefit in the management of 
treatment resistant epilepsy.  CBZ in particular is known to be associated with a vast range of drug to 
drug interactions, some of which may affect the pharmacokinetics of CBZ leading to safety concerns 
due to the narrow therapeutic window.  In addition, CBZ’s potent enzyme inducing effects in the 
liver influence the metabolism of a wide range of drugs for many different conditions.  The 
pharmacokinetic profile of Esli may offer particular benefit to people with multiple co-morbidities, 
concomitant medications, and the elderly.19 
This review identified seven studies that investigated the outcome of transition between CBZ and or 
OXC and ESL, with specific data on the transition dose ratio and scheduling.  The data available 
suggest that the overnight transition between OXC and ESL in a 1:1 ratio (most commonly) is 
generally well tolerated with retention rates between 70 and 100% (5 days to 5 months).  The 
transition to ESL has also demonstrated improvement in adverse events associated with OXC across 
a variety of domains.  Almost 60% of individuals’ who transitioned from OXC to ESL because of 
adverse events experienced no further symptoms at 12 months.15 Any adverse events associated 
with the introduction of ESL itself reduced with time.  The data available suggests no negative impact 
upon seizure control and a responder rate (≥ 50% reduction in seizures) of almost half at 12-month 
follow-up.15 
All of the papers included in this review expect one investigated the transition from immediate 
release OXC to ESL.  There is evidence to demonstrate that OXC extended release formulation is 
associated with better tolerability.20 However, the OXC extended release formation is not available 
in all regions and so this review is clinically relevant. 
There is less data available for comparison on the transition from CBZ to ESL.  The transition ratio 
varied between 1:1.3 and 1:1.5.  Retention rate following transition has been reported as 69% with a 
mean follow up period of four months,14 with almost half of those transitioned from CBZ to ESL 
because of adverse events experiencing no further symptoms.15 The limited data from one 
investigation on efficacy reports a responder rate of almost 40% at 12 month follow up.15 
Hyponatraemia is a clinically important consideration when prescribing dibenzazepines. This review 
only identifies limited data that may help inform prescribing choices.  In a population of individuals 
(N=19) with pre-existing low sodium levels prescribed OXC, there was no significant impact upon 
serum sodium levels on long term follow up (1,6,12, and 18 months), even at higher dosege.12 When 
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an immediate switch was conducted from OXC extended release formulation to ESL decreased 
serum sodium was observed at 5 days in nine of 12 participants.  However, no one experienced 
hyponatraemia of a clinically concerning level requiring intervention or medication change.17 
Non concordance with AEDs is a major contributing factor to treatment failure in epilepsy.21  This can 
lead to significant risks to patient safety including injury, hospitalisation, and sudden unexpected 
death in epilepsy (SUDEP).22  When patients experience side effects from prescribed medications 
adherence is poor.23 Unfortunately the studies included in this review do not identify any specific 
markers of AED concordance such as serum AED levels.  We can therefore only speculate based on 
surrogate markers such as seizure control and retention rates. 
Limitations 
The investigations identified are heterogeneous in terms of sample population, methodology, and 
outcome measures.  Therefore, it has not been possible to pool any available data for further 
analysis.  The studies are observational, with no comparative data such as different dosing ratios or 
schedules for switching between AEDs.  The sample sizes in each study are small, and where samples 
are larger these consist of sub-groups derived from wider investigations. Inclusion and exclusion 
criteria vary between investigations, although the broad base of population characteristics is 
generally similar.  These characteristics include diagnosis of epilepsy, with focal seizures, 
concomitant AED prescription, and treatment resistance- as may be expected given ESL licensing and 
indication.  There is significant risk of inherent bias in all studies included due to the observational 
design, patient selection, sample sizes, short follow-up periods, and lack of comparative groups for a 
randomisation and blinding process.  One positive regarding these observational studies is that 
outcomes may be more pragmatic.  The nature of some of the studies included (conference 
proceedings) does not allow for formal assessment of bias due to lack of data.   
Based on the findings in this review there is Grade C evidence24 available to help guide clinicians on 
when and how to transition patients from CBZ or OXC to ESL.  A Delphi Consensus paper has 
described recommendations (Table 2) on how to switch from CBZ and OXC to ESL.25 This 
recommendation is based upon ESL clinical data and clinical practice experience of 54 epilepsy 
experts.   
Table 2 [INSERT HERE] 
This review does not provide significant new information to influence how transition from OXC or 
CBZ to ESL should be conducted.  The evidence available is based on a transition from both OXC and 
CBZ overnight with some positive outcomes in the limited data set.  There is a lack of data 
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comparing dosing regimens and titration periods.  As discussed, the pharmacokinetic profile of ESL 
may be beneficial for certain populations with particular characteristics.  However, to date there is a 
lack of robust evidence examining whether this benefit is observed in a clinically relevant way. 
Conclusion 
There is low level Grade C evidence24 available based on data from heterogeneous observational 
cohort studies to support the method of transition between older dibenzazepines and ESL.  The data 
that are available from pragmatic observational investigations demonstrates that transition from 
CBZ and or OXC to ESL may be effective, and it is in general well tolerated. The pharmacokinetic 
profile of ESL suggest that it may be beneficial for individuals experiencing side effects from other 
dibenzazepines, lack of efficacy, lowered adherence, and or risk of drug to drug interactions.  
However, at present data to support the switch in particular populations are not available.  There is 
a clear need for a rigorous scientific investigation to be performed in large representative real-world 
cohorts across multiple sites, with comparative groups for transition ratio, schedule, and those who 
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Appendix 1.  Search strategy: Medline, PsychINFO, and the Cochrane Library of Systematic Reviews 
using search term and subject headings for ‘Eslicarbazapine’ and ‘Carbamazapine’ or 












Table 1. Results of systematic literature search 
Article 
 
Setting Sample Transition Dose 
Ratio Schedule 
from OXC or CBZ 
to ESL 
Results and Implications 
Oehl et al, 201112 
Conference Abstract  
Prospective study patients 
with uncontrolled focal 







1:1 after 3 days 
Adverse events 
No significant effect on serum sodium levels 
 




Prospective investigation in 










No difference in AEs, Quality of Life scores, or alertness pre 
and post switch (5 days post switch) 
Decreased serum sodium in 9 of 12 (no clinical concern) 






Adult patients with focal 
epilepsy not seizure free with 






Range 1:1.1 to 1:1.9  
Adverse events: 
(5 days post switch) 
Significantly lower Adverse Event Profile (AEP) (p<0.005) 
-reduction in unsteadiness, GI symptoms, weight gain, 
dizziness, diplopia, impaired concentration 
70% retention rate 
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QOLIE-10* and alertness-no significant changes 





study in adults with 
pharmacoresistant epilepsy 







Sub group: N=25 
Switch CBZ to ESL 
(N=13) 
 
Switch OXC  to ESL 
(N=12) 







CBZ to ESL (N=11 with at least 3 months follow up) 
 
Seizure freedom 1 (9%), responder (≥ 50% reduction in 
seizures) 4 (36.4%), no change 1 (9%), increase in seizure 
frequency 1(9%). 
 
OXC to ESL (N=8 with at least 3 months follow up) 
 
Seizure freedom 1 (12.5%), responder 1 (12.5%), no change 3 
(37.5%), increase in seizure frequency 3 (37.5%). 
 
Adverse events 
CBZ to ESL (N=13) 
8 experienced AEs (dizziness and nausea-4, anxiety-2, 
insomnia-1, constipation-1, pruritic rash-1) 




OXC to ESL (N=12) 
4 experienced AEs (drowsiness) 
2 reported resolution of AEs on switching (dizziness and 
drowsiness) 
Retention rate -100% (5 months)  
6.6% reduced sodium levels, none below 125mmol/L 









 Focal seizures in 12 hospitals 
in Spain who initiated ESL 
between January 2010 and 





CBZ (N=66) 45 
(75%) switch to ESL 
OXC (N=50) 








CBZ to ESL 
12-month responder rate 38.7% with 11.4% seizure free 
(baseline 13%) 
OXC to ESL 




CBZ to ESL 
47.1% switch due to AEs had no further symptoms 
OXC to ESL 
57.7% switch due to AEs had no further symptoms 
Mäkinen et al, 
201716 
 
A prospective single centre 
study of patients on OXC with 
side effects in a hospital 
inpatient setting in Finland  
 




50% reduction n seizure frequency (1) 
30% reduction in seizure frequency (1) 
4 out of 12 reduction in seizure frequency or duration 
Increased seizure frequency (0) 
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*(Quality of Life in Epilepsy Inventory -10) 
 
Adverse events 
15 OXC-related AEs reduced significantly after transitioning.  
93% of the AEs which presented in the morning resolved 
following transition  
100% retention 
ESL related side effects were 39% at month 1 and 13% at 
month 3.  




study for patients with drug-
resistant focal epilepsy on 
stable dose of OXC for at least 
4 weeks. 
 
N=21 Overnight switch 
Individual basis  
OXC:ESL  
1:1 (most commonly) 
Adverse events 
(5 days post switch) 
 AEP score (p<0.01) and alertness (76%) (p<0.5) 






Table 2. The EPICON25 recommendations for transition from CBZ or OXC to ESL. 
A switch from CBZ to ESL over a period of 1 to 3 weeks with a CBZ:ESL dose ratio of 1:1.3. 
Patient characteristics: 
-Low concordance with medication 
-Patients working shift patterns/unusual hours 
-Patients on multiple medications  
-Cognitive problems 
-Severe osteoporosis or osteopenia 
-Dyslipidaemia  
-Liver disease other than acute liver failure 
-Men with erectile dysfunction caused by CBZ.   
A switch from OXC to ESL is well tolerated even with an overnight switch in a 1:1 ratio. 
Patient characteristics: 
-Low concordance with medication 
-Patients working shift patterns/unusual hours 
-Patients on multiple medications 
-Cognitive problems.  
 
*Transition to ESL is not recommended for individuals with a rash associated with CBZ or OXC treatment. 
 
 
